BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Policy

  Teva, Viatris Again Challenge J&J Patent for Schizophrenia Drug with Appeals Court Win

  A federal appeals court Monday backed Teva and Viatris’ challenge to a lower court ruling, finding that the companies can again make their case against Johnson & Johnson’s patent covering its schizophrenia drug Invega Sustenna.

  April 2, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Deals

  Eiger Files for Bankruptcy, Plans to Shutter Operations After Difficult Year

  Following a series of rejections and clinical failures, Eiger BioPharmaceuticals has declared bankruptcy and will sell all its assets as the company winds down operations.

  April 2, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Drug Development

  Gritstone Fails Cancer Vaccine Trial, Plans Phase III and Public Offering

  The biotech’s personalized neoantigen vaccine for colorectal cancer did not demonstrate a molecular response difference from the control arm. Gritstone blames trial protocol and plans for a Phase III study.

  April 2, 2024

   · 

  2 min read

   · 

  Kate Goodwin
• 

  Drug Development

  Roivant Posts Phase II Eye Disease Win for TYK2 Drug, Plans Pivotal Program

  Roivant has chalked up a mid-stage victory for its Pfizer-partnered dual TYK2/JAK1 inhibitor, setting it up to start a Phase III trial in non-anterior non-infectious uveitis this year.

  April 2, 2024

   · 

  2 min read

   · 

  Nick Paul Taylor
• 

  Flush With New $150M Investment, Avenzo Pursues Licensing Strategy

  Avenzo’s founders, who led Turning Point through its $4.1 billion sale to BMS, want to in-license three clinical-stage oncology candidates by early 2026.

  April 2, 2024

   · 

  3 min read

   · 

  Neil Versel
• 

  Drug Development

  Vertex Pushes Oral Drug into Phase III Kidney Disease Trial, Eyes Accelerated Approval

  Following promising Phase IIa data, Vertex Pharmaceuticals will now evaluate its oral drug candidate inaxaplin in a late-stage study of APOL-1 mediated kidney disease.

  April 2, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Drug Development

  Verve Halts Trial for Lead Gene Editing Program Due to Safety Concerns

  Verve Therapeutics is pausing enrollment in the Phase Ib Heart-1 study for its gene editor VERVE-101 after a patient developed grade 3 laboratory abnormalities, the company announced Tuesday.

  April 2, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Drug Development

  Ipsen Inks Potential $900M Deal with Sutro for Global Rights to Preclinical ADC

  Under the agreement, Ipsen nabs exclusive global rights for development and commercialization of Sutro Biopharma’s STRO-003, an antibody-drug conjugate which is completing the final stages of preclinical development.

  April 2, 2024

   · 

  2 min read

   · 

  Tyler Patchen
• 

  Business

  C-Suite Shuffle: Lonza Hires New CEO

  Read the latest overview of people coming and going from executive positions at biopharma companies that BioSpace covers.

  April 2, 2024

   · 

  2 min read

   · 

  Neil Versel
• 

  Drug Development

  The Next Wave of ADCs Could Treat Evasive Solid Tumors

  With second-generation antibody-drug conjugates, Eli Lilly, Daiichi Sankyo and others look to reduce toxicity and improve the magnitude and duration of response.

  April 2, 2024

   · 

  6 min read

   · 

  Heather McKenzie